{"id":872379,"date":"2025-08-07T07:05:18","date_gmt":"2025-08-07T11:05:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-reports-second-quarter-2025-financial-results-and-raises-2025-revenue-guidance\/"},"modified":"2025-08-07T07:05:18","modified_gmt":"2025-08-07T11:05:18","slug":"avadel-pharmaceuticals-reports-second-quarter-2025-financial-results-and-raises-2025-revenue-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-reports-second-quarter-2025-financial-results-and-raises-2025-revenue-guidance\/","title":{"rendered":"Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance"},"content":{"rendered":"
\n

\n — Generated LUMRYZ\u2122 net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 —<\/em>\n <\/p>\n

\n — 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 — <\/em>\n <\/p>\n

\n — Raises 2025 full year revenue guidance to $265 – $275 million —<\/em>\n <\/p>\n

— Received Orphan Drug Designation from FDA for LUMRYZ\u2122 (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH)<\/em> —<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0— On track to complete enrollment in pivotal Phase 3 REVITALYZ\u2122 study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 — <\/em><\/p>\n

\n — <\/em>
\n Avadel management to host conference call today at 8:30 a.m. ET<\/em>
\n —<\/em>\n <\/p>\n

DUBLIN, Ireland, Aug. 07, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today increased its revenue guidance for the year as it announced its financial results for the second quarter ended June 30, 2025.<\/p>\n

\u201cLUMRYZ strengthened its market position and delivered accelerated growth in revenue, positive cash flow and momentum in the second quarter, supported by its strong and growing foundation of prescribers and patients and our 2025 commercial investments,\u201d said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. \u201cOur commercial investments and execution have driven favorable uptake, growing reimbursed patients on therapy, and improved persistency trends generating quarterly net income for the first time since the launch of LUMRYZ in 2023. As such, these encouraging trends give us confidence to raise our guidance, and we now expect full-year revenues to be in the range of $265 – $275 million. With the recent appointment of Susan Rodriguez as our Chief Operating Officer and our enhanced commercial execution, we continue to identify additional opportunities to build on this momentum and capitalize on the differentiated profile of LUMRYZ to become the oxybate of choice for providers and patients.\u201d<\/p>\n

\u201cIn addition to the progress in narcolepsy, Avadel was granted FDA Orphan Drug Designation for LUMRYZ in idiopathic hypersomnia (IH) during Q2,\u201d Mr. Divis commented. \u201cThis designation is particularly encouraging, as it underscores the potential future clinical advantage of LUMRYZ over currently available oxybates in the treatment of IH while we advance towards completion of our Phase 3 REVITALYZ trial.\u00a0Enrollment, targeted at 150 patients, is expected to be complete by the end of 2025 followed by topline data in 2026 to support a potential supplemental NDA filing. If approved, we believe LUMRYZ could transform the treatment of IH, improve care for patients, and further expand the commercial potential in hypersomnolence disorders.\u201d<\/p>\n

\n Second Quarter Highlights and 2025 Guidance:<\/strong>\n <\/p>\n